Advertisement

A Systematic Review of Studies on Heart Transplantation for Patients With End-Stage Chagas’ Heart Disease

Published:December 29, 2008DOI:https://doi.org/10.1016/j.cardfail.2008.10.023

      Abstract

      Background

      Uncertainties regarding indications for the procedure, proper immunosuppressive regimen, and the fear of Trypanosoma cruzi infection reactivation are major concerns regarding heart transplantation (HTx) for patients with end-stage Chagas’ heart disease.

      Methods and Results

      To review indications for HTx, current immunosuppressive therapy, posttransplant morbidities, and outcome in Chagas’ heart transplant recipients. Review of articles linking HTx and Chagas’ disease at PubMed and Scielo database from 1966 onward. HTx can reasonably be indicated in patients with an annual probability of death of 70%. HTx has been associated with a similar incidence of rejection episodes in Chagas’ and non-Chagas’ heart transplant recipients. A lower incidence of infection episodes has been observed in Chagas’ in comparison to non-Chagas’ heart transplant recipients. T. cruzi infection reactivation is easily treated with either benznidazole or allopurinol and portends a very low mortality rate. Other posttransplant morbidities have a similar incidence in Chagas’ and in non-Chagas’ patients. Survival probability for Chagas’ HTx recipients at 1 month, 1 year, 4 years, and 10 years follow-up is 83%, 71%, 57%, and 46%, respectively. Such an outcome is better than that seen in non-Chagas’ heart transplant recipients.

      Conclusions

      HTx is safe and efficacious for patients with end-stage Chagas’ heart disease.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Laranja F.S.
        • Dias E.
        • Nóbrega G.
        • Miranda A.
        Chagas’ disease. A clinical, epidemiologic, and pathologic study.
        Circulation. 1956; 14: 1035-1060
        • Bestetti R.B.
        • Ramos C.P.
        • Figueredo-Silva J.
        • Sales-Neto V.N.
        • Oliveira J.S.M.
        Ability of the electrocardiogram to detect myocardial lesions in isoproterenol-induced rat cardiomyopathy.
        Cardiovasc Res. 1987; 21: 916-921
        • Rassi- Jr., A.
        • Rassi S.G.
        • Rassi A.
        Morte súbita na doença de Chagas.
        Arq Bras Cardiol. 2001; 76: 75-85
        • Bestetti R.
        Stroke in a hospital-derived cohort of patients with chronic Chagas’ heart disease.
        Acta Cardiol. 2000; 55: 33-38
        • Bestetti R.B.
        • Santos C.R.F.
        • Machado Jr., O.B.
        • et al.
        Clinical profile of patients with Chagas' disease before and during ventricular tachycardia.
        Int J Cardiol. 1990; 29: 39-46
        • Rassi- Jr., A.
        • Rassi A.G.
        • Rassi S.G.
        • Rassi- Jr., L.
        • Rassi A.
        Arritmias ventriculares na doença de Chagas. Particularidades diagnósticas, prognósticas e terapêuticas.
        Arq Bras Cardiol. 1995; 65: 377-387
        • Bestetti R.B.
        • Ariolli M.T.
        • Carmo J.L.
        • et al.
        Clinical characteristics of acute myocardial infarction in patients with Chagas' Disease.
        Int J Cardiol. 1992; 35: 371-376
        • Bestetti R.B.
        • Muccillo G.
        Clinical course of Chagas’ heart disease: a comparison with dilated cardiomyopathy.
        Int J Cardiol. 1997; 60: 187-193
        • Bestetti R.B.
        • Dalbo C.M.R.
        • Arruda C.A.
        • Correia-Filho D.
        Predictors of sudden cardiac death for patients with Chagas’ disease: a hospital-derived cohort study.
        Cardiology. 1996; 87: 481-487
        • Bocchi E.A.
        • Bellotti G.
        • Mocelin A.O.
        • et al.
        Heart transplantation for chronic Chagas’ heart disease.
        Ann Thorac Surg. 1996; 61: 1727-1733
        • Bocchi E.A.
        • Fiorelli A.
        The Brazilian experience with heart transplantation: a multicenter report.
        J Heart Lung Transplant. 2001; 20: 637-645
        • Parra A.V.
        • Rodrigues V.C.
        • Cancella S.
        • Cordeiro J.A.
        • Bestetti R.B.
        Impact of socioeconomic status on outcome of a Brazilian heart transplant recipient cohort.
        Int J Cardiol. 2008; 125: 142-143
        • Blanche C.
        • Aleksic I.
        • Takkenberg J.M.
        • Czer L.S.C.
        • Fishbein M.C.
        • Trento A.
        Heart transplantation for Chagas’ cardiomyopathy.
        Ann Thorac Surg. 1995; 60: 1406-1409
        • Freitas H.F.
        • Chizzola P.R.
        • Paes A.T.
        • Lima A.C.
        • Mansur A.J.
        Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease.
        Int J Cardiol. 2005; 102: 239-247
        • Theodoropoulos T.A.D.
        • Bestetti R.B.
        • Otaviano A.P.
        • Cordeiro J.A.
        • Rodrigues V.C.
        • Silva A.C.
        Predictors of all-cause mortality in chronic Chagas’ heart disease in the current era of heart failure therapy.
        Int J Cardiol. 2008; 128: 22-29
        • Mady C.
        • Cardoso R.H.
        • Barreto A.C.P.
        • da Luz P.L.
        • Bellotti G.
        • Pileggi F.
        Survival and predictors of survival in patients with congestive heart failure due to Chagas’ cardiomyopathy.
        Circulation. 1994; 90: 3098-3102
        • Leirner A.A.
        • Moreira L.F.P.
        • Stolf N.A.G.
        The role of circulatory assistance and heart transplantation in Chagas’ disease cardiomyopathy.
        Art Organs. 2007; 31: 245-248
      1. Dib JA, Bestetti RB, Freitas PF, Theodoropoulos TA, Cardinalli-Neto A, Cordeiro JA. Predictors of all-cause mortality for patients with Chagas’ cardiomyopathy listed for heart transplantation. Int J Cardiol 2008 Jul 21. [Epub ahead of print]

        • Cardinalli-Neto A.
        • Bestetti R.B.
        • Cordeiro J.A.
        • Rodrigues V.C.
        Predictors of all-cause mortality for patients with chronic Chagas’ heart disease receiving implantable cardioverter-defibrillator therapy.
        J Cardiovasc Electrophysiol. 2007; 18: 1236-1240
        • Aaronson K.D.
        • Schwartz J.S.
        • Chen T.M.
        • Wong K.L.
        • Goin J.E.
        • Mancini D.M.
        Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation.
        Circulation. 1997; 95: 2660-2667
        • Mehra N.R.
        • Kobashigawa Starling R.
        • et al.
        Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006.
        J Heart Lung Transplant. 2006; 25: 1024-1042
        • Moreira M.C.V.
        • Magalhães H.M.
        • Bordignon S.
        • et al.
        III. Indicação de transplante cardíaco/seleção.
        Arq Bras Cardiol. 1999; 73: 11-20
        • Carvalho V.B.
        • Souza E.F.L.
        • Vila J.H.A.
        • et al.
        Heart transplantation in Chagas’ disease.
        Circulation. 1996; 94: 1815-1817
        • Fiorelli A.I.
        • Stolf N.A.
        • Honorato R.
        • et al.
        Later evolution after cardiac transplantation in Chagas’ disease.
        Transplant Proc. 2005; 37: 2793-2798
        • Bacal F.
        • Silva C.P.
        • Bocchi E.A.
        • et al.
        Mycophenolate Mofetil increased Chagas’ disease reactivation in heart transplanted patients: comparison between two different protocols.
        Am J Transplant. 2005; 5: 2017-2021
        • Bestetti R.B.
        • Souza T.R.
        • Lima M.F.
        • Theodoropoulos T.A.D.
        • Cordeiro J.A.
        • Burdmann E.A.
        Effects of a mycophenolate mofetil-based immunosuppressive regimen in Chagas’ heart transplant recipients.
        Transplantation. 2007; 84: 441-442
        • Bestetti R.B.
        • Theodoropoulos T.A.D.
        • Burdmann E.A.
        • Abbud-Filho M.
        • Cordeiro J.A.
        • Villafanha D.
        Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up.
        Transplantation. 2006; : 81692-81696
        • Souza M.M.
        • Franco M.
        • Almeida D.R.
        • et al.
        Comparative histopathology of endomyocardial biopsies in chagasic and non-chagasic heart transplant recipients.
        J Heart Lung Transplant. 2000; 220: 534-543
        • Taylor D.O.
        • Edwards L.B.
        • Boucek M.A.
        • et al.
        The registry of the International Society for Heart and Lung Transplantation: 22nd official adult heart transplant report-2005.
        J Heart Lung Transplant. 2005; 24: 804
        • Cupoletti A.
        • Perez-Villa F.
        • Vallejos I.
        • Roig E.
        Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
        Transplant Proc. 2005; 37: 4036-4038
        • Kobashigawa J.
        • Miller L.
        • Dale R.
        • et al.
        A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients.
        Transplantation. 1998; 66: 507-515
        • Bocchi E.A.
        • Bellotti G.
        • Uip D.
        • et al.
        Long-term follow up after heart transplantation in Chagas’ disease.
        Transplant Proc. 1993; 25: 1329-1330
        • Kobashigawa J.A.
        • Katznelson S.
        • Laks H.
        • et al.
        Effect of pravastatin on outcomes after cardiac transplantation.
        N Engl J Med. 1995; 333: 621-627
        • Kobashigawa J.
        • Meiser B.M.
        Review of major clinical trials with Mycophenolate Mofetil in cardiac transplantation.
        Transplantation. 2005; 80: S235-S243
        • Sartori A.M.C.
        • Ibrahim K.Y.
        • Westphalen E.V.N.
        • et al.
        Manifestations of Chagas’ disease (American Trypanosomiasis) in patients with HIV/AIDS.
        Ann Trop Med Parasitol. 2007; 101: 31-50
        • Sartori A.M.C.
        • Eluf-Neto J.
        • Nunes E.V.
        • et al.
        Trypanosoma cruzi parasitemia in chronic Chagas’ disease: comparison between human immunodeficiency virus (HIV)-positive and HIV negative patients.
        J Infect Dis. 2002; 186: 872-875
        • Stolf N.A.G.
        • Higushi L.
        • Bocchi E.
        • et al.
        Heart transplantation in patients with Chagas’ disease cardiomyopathy.
        J Heart lung Transplant. 1987; 6: 307-312
        • Couto W.J.
        • Branco J.N.R.
        • Almeida D.
        • et al.
        Transplante cardíaco e infecção.
        Rev Bras Cir Cardiovasc. 2001; 16: 141-151
        • Bestetti R.B.
        • Cury P.M.
        • Theodoropoulos T.A.D.
        • Villafanha D.
        Trypanosoma cruzi infection reactivation presenting as complete atrioventricular block in a Chagas’ heart transplant recipient.
        Cardiovasc Pathol. 2004; 13: 323-326
        • Teixeira V.A.P.
        • Araújo M.B.M.
        • Reis M.A.
        • et al.
        Possible role of an adrenal parasite reservoir in the pathogenesis of Trypanosoma cruzi myocarditis.
        Trans Roy Soc Trop Méd Hyg. 1993; 87: 552-554
        • Schijman A.G.
        • Vigliano C.
        • Burgos J.
        • et al.
        Early diagnosis of recurrence of Trypanosoma cruzi infection by polymerase chain reaction after heart transplantation of a chronic Chagas’ heart disease patient.
        J Heart Lung Transplant. 2000; 19: 114-117
        • Rottenberg M.E.
        • Cardoni R.L.
        • Sinagra A.
        • et al.
        Trypanosoma cruzi: T-cell-dependent mechanisms of resistance during chronic infection.
        Exp Parasitol. 1991; 73: 127-136
        • Boullon F.
        • Sinagra A.
        • Riarte A.
        • et al.
        Experimental cardiac transplantation in chronic Chagas’ disease in dogs.
        Transplant Proc. 1988; 20: 432-437
        • Bestetti R.B.
        • Castilho O.T.
        • Teno L.A.C.
        • Freitas O.C.
        Absence of Trypanosoma cruzi myocardial infection reactivation in Chagas’ heart transplant.
        Cardiovasc Pathol. 1994; 3: 257-259
        • Campos S.V.
        • Strabelli T.M.V.
        • Amato-Neto V.
        • et al.
        Risk factors for Chagas’ disease reactivation after heart transplantation.
        J Heart Lung Transplant. 2008; 27: 597-602
        • Almeida D.R.
        • Carvalho A.C.
        • Branco J.N.
        • et al.
        Chagas’ disease reactivation after heart transplantation: efficacy of allopurinol treatment.
        J Heart Transplant. 1996; 15: 988-992
        • Bocchi E.A.
        • Fiorelli A.
        The paradox of survival results after heart transplantation for cardiomyopathy caused by Trypanosoma cruzi.
        Ann Thorac Surg. 2001; 71: 1833-1838
      2. Diez M, Favaloro L, Bertolloti A, et al. Usefulness of PCR strategies for early diagnosis of Chagas’ disease reactivation and treatment follow up in heart transplantation. Am J Transplant 207;7:1633–1640.